Cardiovascular Concerns in BRCA1 and BRCA2 Mutation Carriers

Kelly C. Gast, Paul V. Viscuse, Somaira Nowsheen, Tufia C Haddad, Robert Mutter, Andrea E Wahner Hendrickson, Fergus J Couch, Kathryn J Ruddy

Research output: Contribution to journalReview article

3 Scopus citations

Abstract

Purpose of review: BRCA1 and BRCA2 mutation carriers can be at increased cardiovascular risk. The goal of this review is to provide information about factors associated with increased cardiovascular risk, methods to prevent cardiovascular toxicities, and recommended screening guidelines. Recent findings: BRCA1/2 mutation carriers who are diagnosed with cancer are often exposed to chemotherapy, chest radiotherapy, and/or HER2 directed therapies, all of which can be cardiotoxic. In addition, BRCA1/2 carriers often undergo prophylactic salpingoopherectomies, which may also increase cardiovascular risks. Summary: Understanding the potential for increased cardiovascular risk in individuals with a BRCA1 or BRCA2 mutation, as well as gold standard practices for prevention, detection, and treatment of cardiac concerns in this population, is important.

Original languageEnglish (US)
Article number18
JournalCurrent Treatment Options in Cardiovascular Medicine
Volume20
Issue number2
DOIs
StatePublished - Feb 1 2018

Keywords

  • BRCA mutation
  • Cardio-oncology
  • Chemotherapy cardiotoxicity
  • Radiation cardiotoxicity

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Fingerprint Dive into the research topics of 'Cardiovascular Concerns in BRCA1 and BRCA2 Mutation Carriers'. Together they form a unique fingerprint.

  • Cite this